glp 1 and colon cancer Emerging Evidence Positions GLP-1 Receptor Agonists as a Novel Strategy to Reduce CRC Risk Diabetes and Colorectal Cancer Risk:
Description
Disclosures R.J.J.: none

Jen : I can see this
Ongoing Research Dr

Nearly half of surveyed payers plan to differentiate the PA process for GLP-1s based on indication, by excluding coverage for obesity and allowing restricted coverage for comorbidities
